

Title: AMR Register: Creation of a new, freely accessible platform for antimicrobial susceptibility data sharing

Authors: Catherine D’Arcy¹, Rebecca Li¹, Patricia A. Bradford² Alisa W. Serio³, Stan Neumann¹,
Nina M. Hill⁴, **Bruce Altevogt**^{*5}




¹Vivli, Inc., Boston, MA, ²Antimicrobial Development Specialists, LLC, Nyack, NY, ³Paratek Pharmaceuticals, Inc., King of Prussia, PA,

⁴Hill Scientific and Public Affairs, LLC, New York, NY, ^{*5}Presenting author, Pfizer, Inc., New York, NY

Background. Understanding patterns and incidence of antimicrobial resistance (AMR) is essential in developing treatment guidance and antimicrobial stewardship programmes. Currently, freely accessible reliable antimicrobial surveillance (AS) data is limited. Yearly reports containing high-level presentation of resistance trends are issued by several multi-national health agencies, however, the data presented are limited to certain organism-drug combinations of general interest. Pharmaceutical companies developing antibiotics receive pre- and post-approval directives to collect AS data to monitor development of resistance over time. The purpose of the AMR Register is to implement a single platform where pharmaceutical companies can share their high quality AS data in the form of minimum inhibitory concentrations (MICs) for individual clinical isolates where healthcare professionals and researchers can access these data for further analysis.

Sets of raw AS data were received from 6 major pharmaceutical companies, including the Pfizer – ATLAS; GSK – SOAR; Johnson and Johnson – DREAM; Paratek – KEYSTONE; Shionogi - SIDERO-WT; and Venatorx - GEARS. Datasets include MIC data from 574 aerobic, anaerobic, fungal and mycobacterial pathogens, tested against 74 antimicrobial agents. Data were provided for more than 968,000 clinical isolates collected during 2004-2021 from 85 countries, including some low- and middle-income countries. Through the AMR Register, individuals are able to access these data and generate analyses of their choosing.




Types of Research being undertaken with the Data:

-  Inform local policies
-  Strengthen understanding of global AMR trends
-  Support Drug Development
-  Drug resistance profile



For more information contact rli@vivli.org

12 requests for data fulfilled since launch



Copenhagen, Denmark
15–18 April 2023

33rd ECCMID

